Reforgene
Latest round
- Series A
Last raised
- Sep 2021
Total raised
- $30M
Investors
- 7
About Reforgene
Established in 2019 and based in Guangzhou, China, Reforgene operates as a gene editing therapy company that focuses on the production and sales of gene and cell therapy drugs. It was recognized as the National High-tech Enterprise. The company has nearly 7000 square meters of research and development sites and pilots. Junbin Liang, the company's CEO, graduated from Sun Yat-sen University and used to work at Shenzhen BGI and the Guangdong Institute of Microbiology, Chinese Academy of Sciences. The company's main business is to develop gene and cell therapy drugs. Combining gene editing, RNA technology and bioinformatics, it develops pipeline drugs for the treatment of thalassemia, malignant tumors and other diseases. The company also provides services such as gene editing tool innovation, drug strategy discovery, new animal model construction, and multi-level efficacy and safety evaluation. The company generates revenue by providing gene and cell therapy drugs and related services.
Who invested in Reforgene
7 investors across 3 rounds
See all investors in Reforgene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Reforgene
Who invested in Reforgene?
Reforgene has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Reforgene raised?
Reforgene has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Reforgene last raise money?
Reforgene's most recent round on record is a Series A, in Sep 2021.
What does Reforgene do?
Established in 2019 and based in Guangzhou, China, Reforgene operates as a gene editing therapy company that focuses on the production and sales of gene and cell therapy drugs.
Where is Reforgene headquartered?
Reforgene is headquartered in Guangzhou, China.
Which VCs invest in companies like Reforgene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Reforgene's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Reforgene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.